cobimetinib ARAF Mutation, +6 more biomarkers Erdheim-Chester Disease, +2 more conditions First line, +1 more context cobimetinib targeted therapy
trametinib ARAF Mutation, +6 more biomarkers Erdheim-Chester Disease, +2 more conditions First line, +1 more context trametinib targeted therapy
bevacizumab + onvansertib + FOLFIRI regimen KRAS Mutation Colorectal Carcinoma Metastatic Second line bevacizumab, +2 more drugs chemotherapy, +1 more type